About Kynurenine 3-monooxygenase
Kynurenine 3-monooxygenase (KMO) is a protein
from Homo sapiens identified by UniProt accession
O15229, 486 residues long.
MolForge cross-references it against 0 known binders and
167 disease associations.
Target properties
| Protein name | Kynurenine 3-monooxygenase |
| UniProt accession | O15229 |
| Gene | KMO |
| Organism | Homo sapiens |
| Length | 486 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (167)
Diseases linked to this target (Open Targets).
- serum metabolite measurement · score 0.31
- urinary metabolite measurement · score 0.31
- lean body mass · score 0.18
- coronary artery disease · score 0.17
- hepatocellular carcinoma · score 0.10
- breast cancer · score 0.09
- triple-negative breast cancer · score 0.09
- neoplasm · score 0.08
- glioblastoma multiforme · score 0.07
- diffuse large B-cell lymphoma · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O15229-F1 | alphafold | PREDICTED | 88.78 | — |
Amino-acid sequence (486 residues)
MDSSVIQRKK VAVIGGGLVG SLQACFLAKR NFQIDVYEAR EDTRVATFTR GRSINLALSH RGRQALKAVG LEDQIVSQGI PMRARMIHSL SGKKSAIPYG TKSQYILSVS RENLNKDLLT AAEKYPNVKM HFNHRLLKCN PEEGMITVLG SDKVPKDVTC DLIVGCDGAY STVRSHLMKK PRFDYSQQYI PHGYMELTIP PKNGDYAMEP NYLHIWPRNT FMMIALPNMN KSFTCTLFMP FEEFEKLLTS NDVVDFFQKY FPDAIPLIGE KLLVQDFFLL PAQPMISVKC SSFHFKSHCV LLGDAAHAIV PFFGQGMNAG FEDCLVFDEL MDKFSNDLSL CLPVFSRLRI PDDHAISDLS MYNYIEMRAH VNSSWFIFQK NMERFLHAIM PSTFIPLYTM VTFSRIRYHE AVQRWHWQKK VINKGLFFLG SLIAISSTYL LIHYMSPRSF LRLRRPWNWI AHFRNTTCFP AKAVDSLEQI SNLISR
Explore Kynurenine 3-monooxygenase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets